• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Co-Diagnostics, Synbiotics launch joint venture CoSara Diagnostics in India

Co-Diagnostics, Synbiotics launch joint venture CoSara Diagnostics in India

July 25, 2017
CenterWatch Staff

Co-Diagnostics, a molecular diagnostics company that has a unique, proprietary platform for the development of diagnostic tests, officially announced the recent incorporation of CoSara Diagnostics, a Joint Venture for manufacturing with Synbiotics. Synbiotics is a group company of Asence, a U.S. incorporated company specializing in supplying pharmaceutical products to international markets.

Co-Diagnostics and Synbiotics incorporated the CoSara entity in India in July. Co-Diagnostics paid for its commitment to CoSara from its recent initial public offering. CoSara intends to secure all applicable regulatory approvals necessary for allowing the sale and distribution of CoSara-branded diagnostics throughout India, with a manufacturing facility expected to be under construction in Q3 2017. Once completed, CoSara will have the exclusive Indian manufacturing rights for Co-Diagnostics products.

Dwight Egan, Co-Diagnostics CEO, commented, “India has been a focal point of our growth plan for several years, and partnering with an outstanding organization such as Synbiotics for in-country manufacturing moves us significantly closer to realizing those goals. Because India has an estimated 400 million cases of tuberculosis from which there are 1,000 deaths each day, it is the ideal market for launching a high-quality, affordable test that can not only have a positive impact on the affected population, but also help to build a strong customer base for our other diagnostic products already in the pipeline.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing